TVTX - Company ID 0001438533
The table below shows Travere Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $93.03M | $58.53M | $58.18M | $61.69M | $165.75M | $84.77M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $80.13M | $27.12M | $21.18M | $16.65M | $15.91M | $15.93M |
| Inventory | $36.16M | $6.20M | $9.41M | $6.92M | $7.31M | $7.61M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $437.56M |
| $416.70M |
| $616.77M |
| $486.44M |
| $582.83M |
| $410.41M |
| Property, plant & equipment | $4.02M | $5.34M | $7.48M | $9.05M | $11.11M | $9.42M |
| Goodwill | - | $800.00K | $800.00K | $900.00K | $900.00K | $936.00K |
| Total assets | $605.19M | $594.13M | $788.91M | $672.59M | $776.63M | $607.44M |
| Accounts payable | $24.80M | $23.53M | $41.67M | $17.29M | $15.14M | $12.13M |
| Total current liabilities | $159.90M | $200.75M | $177.91M | $142.16M | $124.09M | $92.66M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $490.36M | $535.05M | $588.10M | $629.73M | $474.52M | $396.23M |
| Retained earnings | -$1.47B | -$1.45B | -$1.13B | -$1.01B | -$765.97M | -$585.88M |
| Total equity | $114.83M | $59.08M | $200.81M | $42.85M | $302.11M | $211.21M |